01-01-2002 | Original Article
A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation
Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2002
Login to get access